Drug, Cosmetic & Toiletry Wholesaling in the US: Market Size, Businesses & Forecast 2026

The Drug, Cosmetic & Toiletry Wholesaling industry in the US acts as a critical intermediate supply chain bridge, managing the merchant wholesale distribution of prescription pharmaceuticals, over-the-counter medications, cosmetics, and personal hygiene products. The sector's direction is defined by the logistics of highly complex therapeutics, increasing specialty medication pipelines, and advanced automation across distribution facilities. According to official public data from the U.S. Census Bureau, the industry achieved total merchant wholesaler sales of $1,294.1 billion in 2022, representing an 11.4% expansion over previous historical milestones.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Drug, Cosmetic & Toiletry Wholesaling in the US industry cover?

This industry consists of commercial operations primarily focused on the merchant wholesale distribution of biological and medical products, botanical preparations, pharmaceuticals, and consumer toiletries. Wholesalers operating in this space take title to the goods they distribute, managing physical storage and inventory logistics without transforming the underlying products.

• •Product scopes include prescription drugs, proprietary over-the-counter medicines, antiseptics, and dietary supplements.
• •The category also encompasses personal care sundries such as cosmetics, perfumes, colognes, and oral hygiene products.
• •It officially excludes distributors focusing strictly on surgical or dental medical equipment, which occupy distinct wholesale categories.

Who operates in the industry and how is it structured?

The sector comprises two primary operational types: merchant wholesalers who buy and sell goods on their own financial account, and corporate agents or brokers who facilitate business-to-business transactions for a commission fee. Industry relationships are historically stable, relying on long-term supply contracts with major retail pharmacy networks, clinical institutions, and independent hospital groups.

• •Merchant wholesalers handle fulfillment logistics via extensive regional distributions networks.
• •Firms often operate specialized cold-chain infrastructure to accommodate specialized biological materials.
• •A highly centralized corporate structure exists for the national pharmaceutical tier, contrasting with a broader network for cosmetics cosmetic lines.

What drives demand in the industry?

The underlying demand for wholesaling services is fundamentally tethered to aggregate healthcare usage trends, national prescription volumes, and consumer spending on personal grooming. Demographic factors like an aging population directly drive corporate throughput, while clinical advancements require supply chains to adapt to complex delivery regimens.

• •Fluctuations in absolute prescription counts and patient healthcare utilization act as primary demand parameters.
• •The expansion of specialty pharmaceuticals, therapeutic oncology agents, and complex biological therapies accelerates supply chain value.
• •Consumer disposable income changes dictate retail wholesale volumes for premium cosmetics and personal toiletry lines.

Who are the notable companies in the industry?

The competitive ecosystem features an extremely concentrated national tier for general pharmaceutical wholesaling alongside regional niche distributors handling specialty cosmetics or localized pharmaceutical lines. Top-tier operators utilize vast economies of scale, extensive automated distribution networks, and multi-billion-dollar enterprise contracts to defend market positioning.

• •McKesson Corporation is a major market participant, reporting total consolidated revenues of $403.4 billion for its fiscal year ended March 31, 2026.
• •Cencora, Inc. operates as a leading distributor, generating segment revenues of $284.96 billion within its U.S. Healthcare Solutions arm during fiscal year 2025.
• •Cardinal Health, Inc. serves as a key player, utilizing nationwide infrastructure to distribute branded and specialty pharmaceutical products.
• •Herbalife Ltd. acts as a global marketer and distributor of health, wellness, and dietary supplement products across retail and wholesale frameworks.

What are the recent trends and outlook?

The wholesaling infrastructure is undergoing a technological modernization cycle, incorporating artificial intelligence and industrial robotics to counter labor constraints and optimize fulfillment precision. Major organizations are heavily deploying automated distribution facilities to manage specialized cell and gene therapies requiring advanced climate-controlled parameters.

• •McKesson Corporation expanded its next-generation supply chain capabilities by launching a dedicated cell and gene therapy distribution facility in fiscal 2026.
• •Cardinal Health, Inc. expanded automated technology and robotics within its newly deployed fulfillment centers during fiscal 2025 to optimize speed and accuracy.
• •The industry faces a shifting portfolio mix as significant brand-name contracts expire and give way to specialty biosimilars and complex therapies.

How is the industry regulated?

Wholesale operators face stringent legal oversight across multiple federal agencies due to the critical nature of safe pharmaceutical distribution. Organizations must systematically maintain meticulous compliance across facility security protocols, accurate product tracking, and proper controlled-substance oversight to safeguard the commercial supply chain.

• •Wholesalers must maintain full compliance with the Drug Supply Chain Security Act (DSCSA) to achieve product traceability across the United States.
• •Firms operate under strict facility, handling, and licensing standards established by the U.S. Food and Drug Administration (FDA).
• •The distribution of scheduled therapeutic chemicals remains subject to rigorous quotas and reporting protocols mandated by the Drug Enforcement Administration (DEA).

Government, statistical and trade sources used for this Claight analysis.

• U.S. Census Bureau Annual Wholesale Trade Survey 2022 ·
• U.S. Food and Drug Administration (FDA) ·
• McKesson Corporation Annual Report 2026 ·
• Cencora, Inc. Form 10-K Fiscal Year 2025 ·
• Cardinal Health, Inc. Fiscal Year 2025 Sustainable Business Report